Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966029 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1HPGDHSD17B10IDO1 | |
| SCHEMBL961860 | 0.84 | PLA2G4A (0.38) | KDM4EALDH1A1HPGDHSD17B10IDO1 | |
| SCHEMBL961861 | 0.84 | PLA2G4A (0.38) | KDM4EALDH1A1HPGDHSD17B10IDO1 | |
| SCHEMBL965623 | 0.83 | MAPT (0.34) | KDM4EALDH1A1HPGDHSD17B10IDO1 | |
| SCHEMBL966154 | 0.82 | KDM4E (0.35) | KDM4EALDH1A1HPGDHSD17B10IDO1 | |
| SCHEMBL966152 | 0.82 | KDM4E (0.35) | KDM4EALDH1A1HPGDHSD17B10IDO1 | |
| SCHEMBL966026 | 0.81 | CCNC (0.40) | KDM4EALDH1A1HPGDHSD17B10IDO1 | |
| SCHEMBL962734 | 0.76 | ROCK1 (0.34) | ALDH1A1NPC1RAB9AKMT2ARXFP1 | |
| SCHEMBL962735 | 0.76 | ROCK1 (0.34) | ALDH1A1NPC1RAB9AKMT2ARXFP1 | |
| SCHEMBL963039 | 0.75 | PPARG (0.39) | KDM4EALDH1A1HPGDIDO1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | KDM4E 1776/4885ALDH1A1 821/4885HPGD 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.